logo-loader

Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference

Last updated: 09:55 24 Sep 2026 AEST, First published: 08:55 24 Sep 2026 AEST

Alterity Therapeutics CEO David Stamler talked with Proactive at the ASX Small and Mid-Cap Conference about how it’s developing disease modifying therapies, the neurodegenerative diseases market and what’s next for the company.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders.

Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases.

#AlterityTherapeuticsLimited #ProactiveInvestors #DavidStamler #NeurodegenerativeDisease #Biotechnology

Parbo Resources uncovers new greenstone belt at Mount Padbury

Parbo Resources (ASX:PRB) CEO Tim Campbell talked with Proactive's Stephen Gunnion about maiden reverse circulation (RC) drilling results at the Mount Padbury gold project, where drilling has confirmed greenstone beneath previously mapped granite at the GoldenEye prospect, from just 44 metres...

5 hours, 8 minutes ago